Paid in Procedures: The Disclosure Rules Behind the Aesthetic Content on Your Feed

Most people researching a cosmetic procedure now do it the same way. They watch. A creator sits in a treatment chair, narrates the sensation, cuts to a two-week follow-up, and names the practice. It is intimate, it is unscripted in tone, and it does not read like advertising, which is exactly the quality that makes it work.

Some of that content is a patient sharing an experience she paid full price for. Some of it is an advertisement produced under a commercial agreement, in which the treatment was the payment. From the outside, at normal scrolling speed, the two look identical.

That gap is not a gray area in American consumer law. It is the specific thing the Federal Trade Commission regulates, and the agency has spent the last several years tightening the rules that govern it. The rules are not obscure and they are not new. What is remarkable is how much aesthetic content on any given feed appears to have never encountered them.

A discounted procedure is a material connection

The short answer: any benefit that a viewer would not expect, including a discounted or complimentary treatment, is a material connection that has to be disclosed.

The FTC's Endorsement Guides, codified at 16 CFR Part 255, turn on a single concept. If there is a connection between the endorser and the seller that a reasonable audience would not expect, and that connection might affect how much weight the audience gives the endorsement, it has to be disclosed clearly. Cash payment is the obvious case. It is not the only case.

The Guides treat products, services, discounts, gifts, commission-generating affiliate codes, contest entries, and ongoing business relationships as material connections. A creator who receives a treatment worth several thousand dollars at no charge, or at a fraction of the published price, in exchange for content has been compensated in a way the audience cannot see. So has the creator who receives a discount code that pays her a percentage of every booking it generates.

Aesthetic medicine is unusually exposed here for a structural reason. The product is expensive, it is delivered in person, and the compensation is easy to characterize as something else. A comped injectable session looks like a favor between a practice and a loyal patient. Under the Guides, the label on the arrangement does not matter. The question is whether the audience knows.

The disclosure standard is stricter than a hashtag

The short answer: the FTC revised the Guides in June 2023 to define "clear and conspicuous" explicitly, and the definition rules out most of what practices and creators currently do.

The 2023 revision was the first substantive update to the Guides since 2009, and it was pointed at exactly the failure modes social platforms created. A disclosure must be unavoidable. In video, that generally means both audible and visual. It must appear in the same medium as the endorsement, not in a linked profile or a separate post. It cannot be buried below a "more" cutoff, hidden in a block of hashtags, or placed where a viewer would have to take an action to find it.

The revision also broadened who is on the hook. Advertisers, endorsers, and intermediaries such as agencies and marketing platforms can all bear responsibility. The clinic that briefs a creator, supplies the treatment, and reposts the resulting video is not a bystander to that video.

It also addressed a specific device the aesthetic market relies on: tagging. Adding a practice handle to an image of a result is an endorsement of that practice. The Guides now speak to endorsements made through tags in pictures, which closes the argument that a tag is somehow casual rather than promotional.

A platform's built-in "paid partnership" label is useful and it is not automatically sufficient. It is a small, easily missed piece of interface furniture that competes with a full-screen video for attention. The legal standard is not whether a label exists somewhere on the screen. It is whether a viewer actually notices it.

"

The compensation in aesthetic influencer marketing is usually the procedure itself, which is precisely why it does not look like compensation. A wire transfer reads as payment. A comped jawline treatment reads as a friendship.

"

"Results may vary" stopped working in 2009

The short answer: the FTC eliminated the safe harbor for atypical-results disclaimers, so a testimonial showing an exceptional outcome is not cured by small print.

For years, advertisers ran their best case and appended a disclaimer. The 2009 revision of the Guides ended that. If a testimonial depicts results that are not what consumers should generally expect, the advertiser must disclose the results consumers can generally expect. Saying "results may vary" does not substitute for that, because consumer research showed people simply do not discount the claim after reading it.

Layer that onto the FTC's Health Products Compliance Guidance, issued in December 2022, which restated the substantiation standard for health-related claims: competent and reliable scientific evidence, generally meaning well-controlled human clinical testing for the specific claim being made. That standard applies to claims about what a treatment does to the body, and an aesthetic outcome claim is a claim about the body.

Put those together and the implication for a practice is uncomfortable but simple. A promotional post showing an unusually good result, with no indication of what a typical result looks like, is a problem regardless of whether the result is real. Authenticity is not the issue. Representativeness is. This is the same reading problem that governs before-and-after galleries, and social content is a gallery with better lighting and no curation standards at all.

The 2024 rule closed the other door

The short answer: the FTC finalized a trade regulation rule on consumer reviews and testimonials in August 2024, and unlike the Guides, it carries civil penalties.

This distinction matters more than it sounds. The Endorsement Guides are interpretive. They explain how the agency reads Section 5 of the FTC Act, and enforcement runs through that provision. The 2024 rule is a rule. Violations can trigger civil penalties per violation, an amount that adjusts annually for inflation and now sits above fifty thousand dollars.

The rule prohibits a set of practices that appear regularly in aesthetic marketing. Fake or AI-generated reviews written by people who never received the service. Buying positive reviews, or buying negative ones about a competitor. Insider reviews from employees, owners, or their relatives without a clear disclosure of the relationship. Company-controlled sites presented as independent review platforms. Selling or buying followers and engagement to inflate the appearance of a practice's reach.

It also reaches review suppression, which connects directly to a mechanism this publication has covered before. A practice that uses legal threats or contract language to remove unfavorable reviews is operating in the same territory as the non-disparagement and arbitration clauses buried in intake paperwork. The FTC's concern in both cases is not the individual review. It is a review landscape shaped so that only one kind of experience is visible.

Who carries the license, and why that changes the stakes

The short answer: the creator faces reputational exposure, and the practice faces regulatory exposure on three separate fronts.

The federal layer is the FTC. The second layer is professional: state medical boards regulate physician advertising, and the AMA Code of Medical Ethics has long held that physician advertising must be truthful and cannot be misleading, with professional societies applying similar standards to their members. A misleading promotional video does not become a marketing problem instead of a medical one because a third party filmed it.

The third layer is privacy. Patient photographs and treatment details are protected health information. Using them for marketing generally requires a signed authorization, distinct from a consent to treat, and the scope of that authorization matters when an image outlives the campaign it was made for.

Then there is the drug and device layer. Many aesthetic treatments involve prescription products, and the FDA regulates their promotion, including promotional material distributed through social channels. The agency established a decade ago that a social media post promoting a prescription product without risk information is promotional labeling subject to the same requirements as any other advertisement. A short video that names a prescription treatment, shows the outcome, and mentions no risks is not a neutral document.

The practical asymmetry is worth naming. The creator is renting attention. The practice is holding a license, running a facility, and taking on the patients this content brings through the door. That is the same accountability gap that shows up in who is actually performing the treatment once a patient arrives.

The honest summary

Influencer content did not corrupt aesthetic marketing. It industrialized a practice the field already had, which was showing prospective patients its most flattering outcomes and calling the presentation education. What changed is the volume, the intimacy of the format, and the fact that the person delivering the pitch is positioned as a peer rather than a seller.

The federal rules are clearer than most patients assume. Compensation includes procedures, discounts, and affiliate codes. Disclosure has to be unavoidable and in the same medium as the message. Exceptional results require an indication of what typical results look like, and a disclaimer does not fix a claim. Fake, incentivized, and insider reviews are now covered by a rule with penalties attached.

For a patient, none of this needs to become a research project. The useful move is smaller. Notice whether a practice discloses. A clinic that labels its paid content clearly, shows results that are not all spectacular, and does not police its own reviews is demonstrating something about how it operates when nobody is watching, which is the only thing any of this actually measures.

The industry's preferred defense is that everyone knows this content is sponsored. The rules exist because the research says otherwise, and because the language of "natural results" shows how quickly a marketing frame becomes something patients mistake for a clinical one. If disclosure were as obvious as the industry claims, it would cost nothing to make it explicit.